Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Shortages Hamper Ohangwena Vaccination Drive

07/30/2021 | 09:06am EDT

OHANGWENA governor Walde Ndevashiya says many people in the region are willing to get vaccinated against Covid-19, but the acute shortage of vaccines has rendered them unable to do so.

Ndevashiya said the region has run out of the AstraZeneca vaccine and only has Sinopharm that is being offered to those willing to take it.

He said that the shortage is hindering the vaccination drive and delaying the region from achieving its target.

"Most people are keen to get vaccinated. Even in the remote rural areas people are willing to get vaccinated but we have a shortage of vaccines in the region. People are now getting to understand the importance of the vaccines and they are now willing to get vaccinated. I'm sure that once we have enough vaccines, we will vaccinate more people," he said.

The governor said the region had made great strides in vaccinating as many people as possible in the past months and more people continue flocking to vaccination centres, despite the shortage of vaccines.

According to the governor, a large number of people from remote areas of the region are unable to access vaccination points.

He said the regional health directorate has set up a number of vaccination points in some rural areas because not all areas have access to vaccination points.

"Plans are in place to increase the vaccination points in rural areas. There are also outreach services which run mobile vaccination points. Ohangwena is vast and it may be a challenge to access all areas in the region but we are trying our best to ensure that all the people have access to the vaccines," he said.

He urged the inhabitants of the region to go out in large numbers to get vaccinated against the deadly Covid-19 virus. As of 27 July, a total of 8 503 people had received their first doses of Sinopharm and AstraZeneca vaccines in the region.

Copyright The Namibian. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about ASTRAZENECA PLC
09/18ASTRAZENECA : IMFINZI plus chemotherapy tripled patient survival at three years ..
09/18ASTRAZENECA : Enhertu reduced the risk of disease progression or death by 72% vs..
09/18ASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of dis..
09/18ASTRAZENECA : Enhertu demonstrated robust and durable tumour response of 54.9% i..
09/18ASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and..
09/17The case for, and against, COVID-19 vaccine boosters
09/17ASTRAZENECA : Enhertu demonstrated clinically meaningful and durable response in..
09/17ASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically..
09/17AstraZeneca and Daiichi Sankyo Company, Limited Announce ENHERTU® (fam-trastu..
09/17AstraZeneca Sees Positive Results for Enhertu Trial
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 214 M - -
Net income 2021 4 990 M - -
Net Debt 2021 24 654 M - -
P/E ratio 2021 31,1x
Yield 2021 2,54%
Capitalization 172 B 172 B -
EV / Sales 2021 5,57x
EV / Sales 2022 4,50x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 110,77 $
Average target price 136,08 $
Spread / Average Target 22,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC10.09%171 794
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556